Recombinant human interleukin-2 (Shandong Quangang Pharmaceutical)

重组人白细胞介素-2

Report date: 2022/01/14 13:23:58

Base Information

Drug NameRecombinant human interleukin-2 (Shandong Quangang Pharmaceutical)
Drug Alias Name泉奇
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterleukin-2 receptor agonists
TargetsInterleukin-2 receptor
Therapy Area/IndicationsAscitesAutoimmune DiseasesLung Neoplasms +[7] 
Global Approved IndicationsAscitesAutoimmune DiseasesLung Neoplasms +[7] 
Approved Indications in ChinaAscitesAutoimmune DiseasesLung Neoplasms +[7] 
Original Approved Country/TerritoryMainland China
Original Approved Date2001/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesShandong Quangang Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShandong Quangang Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsAscitesAutoimmune DiseasesLung Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeL03AC01
Related LinksN/A